Skip to main content
. Author manuscript; available in PMC: 2021 Mar 6.
Published in final edited form as: Leukemia. 2020 Jul 6;35(3):752–763. doi: 10.1038/s41375-020-0951-5

Fig. 7. Biomarkers of disease burden in a patient treated with Descartes-08.

Fig. 7

Serum samples were collected from patient 103–016 in NCT03448978 and analyzed for free immunoglobulin light chains (a) or by soluble BCMA (sBCMA) ELISA (b). Arrows indicate days of infusion of Descartes-08 on days 0, 3, and 7. NHS indicates measured level in a sample of normal human serum from pooled normal donors. A 3.8-fold drop in sBCMA level was observed from peak level till Day 29 post infusion. *P<.05, ***P<.001